John Galluzzi

John Galluzzi is an experienced oncology account specialist at Regeneron Pharmaceuticals, Inc., since January 2020, focusing on Libtayo (cemiplimab). Prior to this role, John worked as an oncology sales representative at Merck from February 2016 to January 2020, promoting Keytruda (pembrolizumab) and Emend. John's career began at Schering-Plough, where responsibilities included promoting anti-infective and anti-fungal products across various medical specialties. Previous experience also includes significant roles at Eisai, Salix/Valeant Pharmaceuticals, where John launched Ruconest for Hereditary Angioedema and earned multiple awards, reflecting a strong track record in specialty pharmaceuticals and oncology sales. John holds a Bachelor of Science degree from Northern Illinois University.